CMS Reviewing Comments on Medicaid Drug Pricing Proposed Rule

by Admin | May 22, 2012 1:28 pm

May 22, 2012—Regulations implementing health care reform’s Medicaid drug rebate provisions should encourage “shared savings” arrangements between 340B covered entities and Medicaid agencies, provider groups urged in comments filed with the Centers for Medicare and Medicaid Services (CMS).

Drug manufacturers, meanwhile, asked CMS to exempt any prices charged to 340B covered entities from their Medicaid best price computations as well as any 340B sales to covered entities that do not abide by program requirements.  

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

Source URL: https://340binformed.org/2012/05/cms-reviewing-comments-on-medicaid-drug-pricing-proposed-rule/

---